Metabolomic screening of tumor tissue and serum in glioma patients reveals diagnostic and prognostic information

Metabolites

Volumn 5, Issue 3, 2015, Pages 502-520

  Mörén, Lina ^a   Tommy Bergenheim, A ^a   Ghasimi, Soma ^a   Brännström, Thomas ^a   Johansson, Mikael ^a   Antti, Henrik ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Blood; Chemometrics; Diagnosis; Glioma; Latent biomarkers; Metabolomics; Prognosis; Tumor

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOISOCAPROIC ACID; 4 AMINOBUTYRIC ACID; CREATININE; CYSTEINE; GLYCEROL 2 PHOSPHATE; LYSINE; RIBITOL;

ARTICLE; ASTROCYTOMA; BIOINFORMATICS; BLOOD ANALYSIS; CANCER GRADING; CANCER SURVIVAL; CHEMOMETRICS; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA PROCESSING; DIFFERENTIAL DIAGNOSIS; DISCRIMINANT ANALYSIS; GAS CHROMATOGRAPHY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METABOLOMICS; OLIGODENDROGLIOMA; PATTERN RECOGNITION; PRINCIPAL COMPONENT ANALYSIS; PROGNOSTIC ASSESSMENT; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 85006215473     PISSN: None     EISSN: 22181989     Source Type: Journal    
DOI: 10.3390/metabo5030502     Document Type: Article

References (47)

1. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K. WHO Classification of Tumours of the Central Nervous System; World Health Organization: Geneva, Switzerland, 2007.
2. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114, 97–109.
3. Tanaka, G.; Nakazato, Y.; Irie, T.; Okada, T.; Abe, M. Indeterminacy in the WHO classification of tumors: An example of the histopathological diagnosis of brain tumors. Brain Tumor pathol. 2011, 28, 247–251.
4. Sanai, N.; Polley, M.Y.; McDermott, M.W.; Parsa, A.T.; Berger, M.S. An extent of resection threshold for newly diagnosed glioblastomas. J. Neurosurg. 2011, 115, 3–8.
5. Chang, E.F.; Smith, J.S.; Chang, S.M.; Lamborn, K.R.; Prados, M.D.; Butowski, N.; Barbaro, N.M.; Parsa, A.T.; Berger, M.S.; McDermott, M.M. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J. Neurosurg. 2008, 109, 817–824.
6. Catalan-Uribarrena, G.; Bilbao-Barandica, G.; Pomposo-Gaztelu, I.; Undabeitia-Huertas, J.; Ruiz de Gopegui-Ruiz, E.; Galbarriatu-Gutierrez, L.; Canales-Llantada, M.; Aurrecoechea-Obieta, J.; Igartua-Azkune, A.; Carbayo-Lozano, G. Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis. Acta Neurochir. 2012, 154, 211–222; discussion 222.
7. Johnson, D.R.; O’Neill, B.P. Glioblastoma survival in the United States before and during the temozolomide era. J. Neuro-oncol. 2012, 107, 359–364.
8. Helseth, R.; Helseth, E.; Johannesen, T.B.; Langberg, C.W.; Lote, K.; Ronning, P.; Scheie, D.; Vik, A.; Meling, T.R. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol. Scand. 2010, 122, 159–167.
9. Ramirez, C.; Bowman, C.; Maurage, C.A.; Dubois, F.; Blond, S.; Porchet, N.; Escande, F. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors—Towards individualized tumor treatment? Neuro-oncology 2010, 12, 490–499.
10. Weller, M.; Felsberg, J.; Hartmann, C.; Berger, H.; Steinbach, J.P.; Schramm, J.; Westphal, M.; Schackert, G.; Simon, M.; Tonn, J.C.; et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J. Clin. Oncol. 2009, 27, 5743–5750.
11. Cairncross, J.G.; Ueki, K.; Zlatescu, M.C.; Lisle, D.K.; Finkelstein, D.M.; Hammond, R.R.; Silver, J.S.; Stark, P.C.; Macdonald, D.R.; Ino, Y.; et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 1998, 90, 1473–1479.
12. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L.; et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352, 997–1003.
13. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J.; et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360, 765–773.
14. Robertson, T.; Koszyca, B.; Gonzales, M. Overview and recent advances in neuropathology. Part 1, Central nervous system tumours. Pathology 2011, 43, 88–92.
15. Verhaak, R.G.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98–110.
16. Saraswathy, S.; Crawford, F.W.; Lamborn, K.R.; Pirzkall, A.; Chang, S.; Cha, S.; Nelson, S.J. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J. Neuro-oncol. 2009, 91, 69–81.
17. Nakamizo, S.; Sasayama, T.; Shinohara, M.; Irino, Y.; Nishiumi, S.; Nishihara, M.; Tanaka, H.; Tanaka, K.; Mizukawa, K.; Itoh, T.; et al. GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. J. Neuro-Oncol. 2013, 113, 65–74.
18. Erb, G.; Elbayed, K.; Piotto, M.; Raya, J.; Neuville, A.; Mohr, M.; Maitrot, D.; Kehrli, P.; Namer I.J. Toward improved grading of malignancy in oligodendrogliomas using metabolomics. Magn. Reson. Med. 2008, 59, 959–965.
19. Cuellar-Baena, S.; Morales, J.M.; Martinetto, H.; Calvar, J.; Sevlever, G.; Castellano, G.; Cerda-Nicolas, M.; Celda, B.; Monleon, D. Comparative metabolic profiling of paediatric ependymoma, medulloblastoma and pilocytic astrocytoma. Int. J. Mol. Med. 2010, 26, 941–948.
20. Jonsson, P.; Johansson, E.S.; Wuolikainen, A.; Lindberg, J.; Schuppe-Koistinen, I.; Kusano, M.; Sjostrom, M.; Trygg, J.; Moritz, T.; Antti, H. Predictive metabolite profiling applying hierarchical multivariate curve resolution to GC-MS datas—A potential tool for multi-parametric diagnosis. J. Proteome Res. 2006, 5, 1407–1414.
21. Law, M.; Yang, S.; Wang, H.; Babb, J.S.; Johnson, G.; Cha, S.; Knopp, E.A.; Zagzag, D. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am. J. Neuroradiol. 2003, 24, 1989–1998.
22. Chinnaiyan, P.; Kensicki, E.; Bloom, G.; Prabhu, A.; Sarcar, B.; Kahali, S.; Eschrich, S.; Qu, X.; Forsyth, P.; Gillies, R. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res. 2012, 72, 5878–5888.
23. Meixensberger, J.; Herting, B.; Roggendorf, W.; Reichmann, H. Metabolic patterns in malignant gliomas. J. Neuro-oncol. 1995, 24, 153–161.
24. Quon, H.; Brunet, B.; Alexander, A.; Murtha, A.; Abdulkarim, B.; Fulton, D.; Smerdely, M.; Johnson, M.; Urtasun, R.; Patel, S.; et al. Changes in serial magnetic resonance spectroscopy predict outcome in high-grade glioma during and after postoperative radiotherapy. Anticancer Res. 2011, 31, 3559–3565.
25. Wibom, C.; Surowiec, I.; Moren, L.; Bergstrom, P.; Johansson, M.; Antti, H.; Bergenheim, A.T. Metabolomic patterns in glioblastoma and changes during radiotherapy: A clinical microdialysis study. J. Proteome Res. 2010, 9, 2909–2919.
26. Majos, C.; Bruna, J.; Julia-Sape, M.; Cos, M.; Camins, A.; Gil, M.; Acebes, J.J.; Aguilera, C.; Arus, C. Proton MR spectroscopy provides relevant prognostic information in high-grade astrocytomas. AJNR Am. J. Neuroradiol. 2011, 32, 74–80.
27. Peeling, J.; Sutherland, G. High-resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms. Magn. Reson. Med. 1992, 24, 123–136.
28. Wyss, M.; Kaddurah-Daouk, R. Creatine and creatinine metabolism. Physiol. Rev. 2000, 80, 1107–1213.
29. Faria, A.V.; Macedo, F.C., Jr.; Marsaioli, A.J.; Ferreira, M.M.; Cendes, F. Classification of brain tumor extracts by high resolution (1)H MRS using partial least squares discriminant analysis. Braz. J. Med. Biol. Res. 2011, 44, 149–164.
30. Bianchi, L.; De Micheli, E.; Bricolo, A.; Ballini, C.; Fattori, M.; Venturi, C.; Pedata, F.; Tipton, K.F.; Della Corte, L. Extracellular levels of amino acids and choline in human high grade gliomas: An intraoperative microdialysis study. Neurochem. Res. 2004, 29, 325–334.
31. Ward, P.S.; Thompson, C.B. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21, 297–308.
32. Sontheimer, H. A role for glutamate in growth and invasion of primary brain tumors. J. Neurochem. 2008, 105, 287–295.
33. Ye, Z.C.; Sontheimer, H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 1999, 59, 4383–4391.
34. Bergenheim, A.T.; Roslin, M.; Ungerstedt, U.; Waldenstrom, A.; Henriksson, R.; Ronquist, G. Metabolic manipulation of glioblastoma in vivo by retrograde microdialysis of L-2, 4 diaminobutyric acid (DAB). J. Neuro-oncol. 2006, 80, 285–293.
35. Marcus, H.J.; Carpenter, K.L.; Price, S.J.; Hutchinson, P.J. In vivo assessment of high-grade glioma biochemistry using microdialysis: A study of energy-related molecules, growth factors and cytokines. J. Neuro-oncol. 2010, 97, 11–23.
36. Wright, A.J.; Fellows, G.A.; Griffiths, J.R.; Wilson, M.; Bell, B.A.; Howe, F.A. Ex-vivo HRMAS of adult brain tumours: Metabolite quantification and assignment of tumour biomarkers. Mol. Cancer 2010, 9, 66.
37. Castillo, M.; Smith, J.K.; Kwock, L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. Am. J. Neuroradiol. 2000, 21, 1645–1649.
38. Kallenberg, K.; Bock, H.C.; Helms, G.; Jung, K.; Wrede, A.; Buhk, J.H.; Giese, A.; Frahm, J.; Strik, H.; Dechent, P.; et al. Untreated glioblastoma multiforme: Increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton mr spectroscopy. Radiology 2009, 253, 805–812.
39. Kinoshita, Y.; Yokota, A. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed. 1997, 10, 2–12.
40. Da Rocha, A.B.; Mans, D.R.A.; Regner, A.; Schwartsmann, G. Targeting protein kinase C: New therapeutic opportunities against high-grade malignant gliomas? Oncologist 2002, 7, 17–33.
41. Righi, V.; Andronesi, O.C.; Mintzopoulos, D.; Black, P.M.; Tzika, A.A. High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. Int. J. Oncol. 2010, 36, 301–306.
42. Jonsson, P.; Gullberg, J.; Nordstrom, A.; Kusano, M.; Kowalczyk, M.; Sjostrom, M.; Moritz, T. A strategy for identifying differences in large series of metabolomic samples analyzed by GC/MS. Anal. Chem. 2004, 76, 1738–1745.
43. Jonsson, P.; Johansson, A.I.; Gullberg, J.; Trygg, J.A.J.; Grung, B.; Marklund, S.; Sjostrom, M.; Antti, H.; Moritz, T. High-throughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses. Anal. Chem. 2005, 77, 5635–5642.
44. Wold, S.; Esbensen, K.; Geladi, P. Principal component analysis. Chemom. Intell. Lab. Syst. 1987, 2, 37–52.
45. Trygg, J.; Wold, S. Orthogonal projections to latent structures (O-PLS). J. Chemom. 2002, 16, 119–128.
46. Eriksson, L.; Trygg, J.; Wold, S. CV-ANOVA for significance testing of PLS and OPLS (R) models. J. Chemom. 2008, 22, 594–600.
47. ROCCET: ROC Curve Explorer & Tester. Available online: www.roccet.ca (accessed on 8 September 2015).